[{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"GB002","moa":"HIF-1-alpha","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aadi Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aadi Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Nab-Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Phase II","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aadi Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aadi Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Nab-Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Phase II","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aadi Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aadi Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Nab-Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Phase II","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aadi Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aadi Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Nab-Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Phase II","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aadi Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aadi Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Nab-Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Phase II","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aadi Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aadi Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Nab-Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Phase II","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aadi Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aadi Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Nab-Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aadi Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aadi Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Nab-Sirolimus","moa":"mTOR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aadi Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aadi Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"Receptor-type tyrosine-protein phosphatase beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aadi Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aadi Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"Receptor-type tyrosine-protein phosphatase beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aadi Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aadi Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"Receptor-type tyrosine-protein phosphatase beta","graph1":"Undisclosed","graph2":"Phase I","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aadi Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aadi Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"Receptor-type tyrosine-protein phosphatase beta","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aadi Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aadi Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"Receptor-type tyrosine-protein phosphatase beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aadi Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aadi Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"ABI-009","moa":"Serine\/threonine-protein kinase mTOR (mTOR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Aadi Bioscience \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Aadi Bioscience \/ National Cancer Institute"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"ABI-009","moa":"Serine\/threonine-protein kinase mTOR (mTOR)","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aadi Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aadi Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"ABI-009","moa":"Serine\/threonine-protein kinase mTOR (mTOR)","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aadi Bioscience \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Aadi Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Robert Ramirez","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"ABI-009","moa":"Serine\/threonine-protein kinase mTOR (mTOR)","graph1":"Oncology","graph2":"Phase II","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Aadi Bioscience \/ Robert Ramirez","highestDevelopmentStatusID":"8","companyTruncated":"Aadi Bioscience \/ Robert Ramirez"}]
Find Clinical Drug Pipeline Developments & Deals by Aadi Bioscience
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
